Feb. 20, 2013 ? Doctors should not be discouraged from prescribing isotretinoin to adolescents for inflammatory acne, according to a new study by Canadian and U.S. scientists showing the drug does not increase the risk of inflammatory bowel disease (IBD).
Led by Dr. Mahyar Etminan of the Child & Family Research Institute at BC Children's Hospital, the Provincial Health Services Authority and the University of British Columbia, the scientists addressed this important drug safety question because of a previous study linking the drug to IBD. In this new report published February 20, 2013 in the medical journal JAMA Dermatology, Dr. Etminan's team says theirs is the first to statistically adjust for severe acne, which is a strong confounding variable that may have led to the overestimation of risk in the earlier study.
The JAMA Dermatology report covered two studies. In one study, the researchers analyzed the health records of a large population of U.S. women between 24-34 years of age. Of the women, 2159 had IBD and 43,180 did not. Only 10 (0.46 per cent) of the women with IBD and only 191 (0.44 per cent) of the women who did not have IBD had used isotretinoin. In the second study, the researchers comprehensively reviewed and analyzed the results of published and unpublished studies. They did not find that isotretinoin increases the risk of IBD.
"We've come to the conclusion that there's no risk that the drug causes inflammatory bowel disease," says Dr. Etminan. "This drug is used for very severe acne that is very traumatic with psychological effects, and it is very effective. Hopefully with this study, it may put dermatologists at ease with prescribing this drug to children and adolescents, knowing that it doesn't cause this adverse effect."
This research was unfunded. Dr. Etminan is a scientist with the Therapeutic Evaluation Unit at the Child & Family Research Institute and the Provincial Health Services Authority. He is appointed in the Faculty of Medicine at the University of British Columbia. The study was co-led by Dr. James Brophy of McGill University.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Child & Family Research Institute.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Mahyar Etminan et al. Isotretinoin and Risk for Inflammatory Bowel Disease
A Nested Case-Control Study and Meta-analysis of Published and Unpublished Data Isotretinoin and Risk for IBD. JAMA Dermatology, 2013; 149 (2): 216 DOI: 10.1001/jamadermatol.2013.1344
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/top_health/~3/Kaz9UbyZSj4/130221092004.htm
the vow review luol deng culkin wooly mammoth no child left behind no child left behind neurofibromatosis
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন